ITGAM and neoplasm: More recently, MDSC-specific “peptibodies” were developed to successfully deplete both subsets of MDSCs in the blood, spleen and tumor of tumor-challenged mice, inhibiting tumor growth with minimal adverse reactions during a multi-dose regimen; however, bone marrow CD11b+Gr1+ iMC were not affected, resulting in replenishment of systemic MDSCs at day 3 following single-dose treatment conditions [21].